Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung

Trial Profile

A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs Bemcentinib (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors BerGenBio
  • Most Recent Events

    • 06 Nov 2018 According to a BerGenBio media release, results from the trial will be presented at the annual Society for Immunotherapy in Cancer (SITC) 2018 congress.
    • 06 Nov 2018 Results presented in a BerGenBio media release.
    • 02 Nov 2018 According to a BerGenBio media release, data from the analysis of the first stage of this trial will be presented at the annual Society for Immunotherapy in Cancer (SITC) 2018 congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top